Laura Joszt

Laura is the editorial director of The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®'s parent company, MJH Life Sciences®, since 2011. She has an MA in business and economic reporting from New York University.

You can reach her at ljoszt@mjhlifesciences.com or you can connect with her on LinkedIn or Twitter.

Biosimilar Competition and Utilization Uptake Have Driven Down Costs in the Oncology Space

April 01, 2022

Article

During a session at the Academy of Managed Care Pharmacy annual meeting, Yuqian Liu, PharmD, of Magellan Rx Management, highlighted strategies to encourage biosimilar utilization in the oncology space and the cost savings as a result.

Improved Biosimilar Uptake Saved Health System $26.9M Over 2 Years

March 28, 2022

Article

A series of initiatives to improve uptake of the biosimilars for 7 originator biologics resulted in significant savings for Providence St. Joseph Health.

Hospitals, Physician Offices Significantly Mark Up Prices for 3 Drugs With Biosimilars

February 21, 2022

Article

A report from AHIP found 3 drugs that have multiple biosimilars available can be delivered more affordably through specialty pharmacies.

Biogen to Sell Its Stake in the Biosimilar Venture Samsung Bioepis

January 28, 2022

Article

In a deal to sell the 50% ownership stake, Biogen would receive up to $2.3 billion.

ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis

July 01, 2020

Article

The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).

Gottlieb Stepping Down as FDA Commissioner

March 06, 2019

Article

FDA Commissioner Scott Gottlieb, MD, will be stepping down from his post in 1 month.

Session Highlights Barriers to Biosimilar Adoption and Lack of Provider, Payer Education

April 17, 2018

Article

During a session at the 2018 Community Oncology Conference, hosted by the Community Oncology Alliance April 12-13 in National Harbor, Maryland, Robert M. Rifkin, MD, FACP, medical director of biosimilars at McKesson Specialty Health, The US Oncology Network, highlighted the opportunities biosimilars provide to increase access to drugs while decreasing costs, but also the remaining barriers to adoption.

New Online Consultation Tool Empowers Patients With Rheumatic Diseases, Study Finds

November 09, 2017

Article

Chinese researchers employed a new online consultation tool to improve disease management for patients with rheumatic diseases who travel long distances for a consultation with their rheumatologist and noted significant savings for the patients.

Obese Patients With Rheumatoid Arthritis Less Likely to Achieve Remission

November 08, 2017

Article

Research presented at the 2017 American College of Rheumatology Annual Meeting found that patients with rheumatoid arthritis and higher body mass index were less likely to achieve remission and more likely to face higher rates of disability.

Study Explores Factors That Predict RA Candidates for Successful DMARD Tapering

November 07, 2017

Article

Researchers identify factors that make certain patients with rheumatoid arthritis good candidates for successfully tapering biologic DMARD dose.